On April 19th, Njurfonden published an interview with iCoat Medical’s Chief Medical Officer Alireza Biglarnia highlighting his research and iCoat Medical’s ongoing First In Human-trial.
“We are grateful for the support from Njurfonden and the vote of confidence in our research that will help us to gain important knowledge on early activation of the immune system after organ transplantation and its influence on patient outcome. These new insights are necessary for development of new treatment modalities to improve the overall patient outcome after organ or tissue transplantation.” says iCoat Medical’s CMO Alireza Biglarnia.
Article in Swedish, link below:
For more information, please contact:
Alireza Biglarnia, CMO – iCoat Medical AB
Peder Waern, CEO – iCoat Medical AB